Observational Trial With Leios/Alesse

This study has been completed.
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
First received: May 31, 2007
Last updated: December 7, 2007
Last verified: December 2007
A prospective, observational study (Anwendungsbeobachtung [AWB]) of the prescribing and administration practices of German gynecologists with Leios® Dragées.

Condition Intervention Phase
Contraceptives, Oral, Combined
Drug: Leios/Alesse
Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Prospective Observation Study (Anwendungsbeobachtung [AWB]) of the Prescribing and Administration Practices of German Gynecologists With Leios® Dragées/Alesse

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Study Start Date: May 2005
Study Completion Date: March 2007

Ages Eligible for Study:   up to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy, women, aged under 40
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00481650

Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Trial Manager For Germany, medinfoDEU@wyeth.com
  More Information

ClinicalTrials.gov Identifier: NCT00481650     History of Changes
Other Study ID Numbers: 101742 
Study First Received: May 31, 2007
Last Updated: December 7, 2007
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

ClinicalTrials.gov processed this record on May 30, 2016